These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24063976)

  • 1. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
    Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
    Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
    J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
    Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
    Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
    Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
    Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
    J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.
    Andreasen LV; Hansen LB; Andersen P; Agger EM; Dietrich J
    Vaccine; 2015 Apr; 33(15):1873-9. PubMed ID: 25698487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
    Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
    Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
    Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
    Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
    Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM
    Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.
    Bravo LC; Carlos JC; Gatchalian SR; Montellano MEB; Tabora CFCB; Thierry-Carstensen B; Tingskov PN; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV
    Vaccine; 2020 Jan; 38(3):530-538. PubMed ID: 31703934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
    Sun M; Li C; Xu W; Liao G; Li R; Zhou J; Li Y; Cai W; Yan D; Che Y; Ying Z; Wang J; Yang H; Ma Y; Ma L; Ji G; Shi L; Jiang S; Li Q
    Clin Infect Dis; 2017 May; 64(10):1317-1325. PubMed ID: 28419204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.